These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

11295 related articles for article (PubMed ID: 15318702)

  • 1. [Phase I-II trial of gene therapy with tag-7 modified autologous tumor cells in patients with metastatic solid tumors].
    Moiseenko VM; Danilov AO; Baldueva IA; Danilova AB; Tiukavina NV; Larin SS; Kiselev SL; Orlova RV; Semenova AI; Turkevich EA; Shchelkina LA; Anisimov VV; Gafton GI; Kochnev VA; Barchuk AS; Kanaev SV; Khanson KP; Georgiev GP
    Vopr Onkol; 2004; 50(3):293-303. PubMed ID: 15318702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma.
    Dudek AZ; Mescher MF; Okazaki I; Math VT; Luo X; Curtsinger JM; Miller JS
    Am J Clin Oncol; 2008 Apr; 31(2):173-81. PubMed ID: 18391603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma.
    Fishman M; Hunter TB; Soliman H; Thompson P; Dunn M; Smilee R; Farmelo MJ; Noyes DR; Mahany JJ; Lee JH; Cantor A; Messina J; Seigne J; Pow-Sang J; Janssen W; Antonia SJ
    J Immunother; 2008 Jan; 31(1):72-80. PubMed ID: 18157014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
    Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE
    Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma.
    Galanis E; Burch PA; Richardson RL; Lewis B; Pitot HC; Frytak S; Spier C; Akporiaye ET; Peethambaram PP; Kaur JS; Okuno SH; Unni KK; Rubin J
    Cancer; 2004 Dec; 101(11):2557-66. PubMed ID: 15517589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA.
    Kyte JA; Mu L; Aamdal S; Kvalheim G; Dueland S; Hauser M; Gullestad HP; Ryder T; Lislerud K; Hammerstad H; Gaudernack G
    Cancer Gene Ther; 2006 Oct; 13(10):905-18. PubMed ID: 16710345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma.
    Berntsen A; Geertsen PF; Svane IM
    Eur Urol; 2006 Jul; 50(1):34-43. PubMed ID: 16675096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [An improved procedure for autologous gene-modified cancer vaccine preparation for active specific immunotherapy of disseminated solid tumors].
    Danilov AO; Larin SS; Danilova AB; Moiseenko VM; Baldueva IA; Kiselev SL; Turkevich EA; Barchuk AS; Anisimov VV; Gafton GI; Kochnev VA; Khanson KP
    Vopr Onkol; 2004; 50(2):219-27. PubMed ID: 15176227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma.
    Safwat A; Schmidt H; Bastholt L; Fode K; Larsen S; Aggerholm N; von der Maase H
    Radiother Oncol; 2005 Nov; 77(2):143-7. PubMed ID: 16216360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. M-Vax: an autologous, hapten-modified vaccine for human cancer.
    Berd D
    Expert Rev Vaccines; 2004 Oct; 3(5):521-7. PubMed ID: 15485331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.
    Luiten RM; Kueter EW; Mooi W; Gallee MP; Rankin EM; Gerritsen WR; Clift SM; Nooijen WJ; Weder P; van de Kasteele WF; Sein J; van den Berk PC; Nieweg OE; Berns AM; Spits H; de Gast GC
    J Clin Oncol; 2005 Dec; 23(35):8978-91. PubMed ID: 16260696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma.
    Oki Y; McLaughlin P; Fayad LE; Pro B; Mansfield PF; Clayman GL; Medeiros LJ; Kwak LW; Srivastava PK; Younes A
    Cancer; 2007 Jan; 109(1):77-83. PubMed ID: 17133412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study.
    Wei YC; Sticca RP; Li J; Holmes LM; Burgin KE; Jakubchak S; Bouton-Verville H; Williamson J; Meyer K; Evans L; Martin J; Stephenson JJ; Trocha S; Smith S; Wagner TE
    Oncol Rep; 2007 Sep; 18(3):665-71. PubMed ID: 17671717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial.
    Arai S; Meagher R; Swearingen M; Myint H; Rich E; Martinson J; Klingemann H
    Cytotherapy; 2008; 10(6):625-32. PubMed ID: 18836917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
    Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
    Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine therapy in patients with renal cell carcinoma.
    Van Poppel H; Joniau S; Van Gool SW
    Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.
    Di Nicola M; Carlo-Stella C; Mortarini R; Baldassari P; Guidetti A; Gallino GF; Del Vecchio M; Ravagnani F; Magni M; Chaplin P; Cascinelli N; Parmiani G; Gianni AM; Anichini A
    Clin Cancer Res; 2004 Aug; 10(16):5381-90. PubMed ID: 15328176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients.
    Lesimple T; Neidhard EM; Vignard V; Lefeuvre C; Adamski H; Labarrière N; Carsin A; Monnier D; Collet B; Clapisson G; Birebent B; Philip I; Toujas L; Chokri M; Quillien V
    Clin Cancer Res; 2006 Dec; 12(24):7380-8. PubMed ID: 17189411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma.
    Pashenkov M; Goëss G; Wagner C; Hörmann M; Jandl T; Moser A; Britten CM; Smolle J; Koller S; Mauch C; Tantcheva-Poor I; Grabbe S; Loquai C; Esser S; Franckson T; Schneeberger A; Haarmann C; Krieg AM; Stingl G; Wagner SN
    J Clin Oncol; 2006 Dec; 24(36):5716-24. PubMed ID: 17179105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 565.